demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 prophylaxis (excluding children)
protein subunit vaccine
Nuvaxovid (NVX-CoV2373) Novavax Novavax PREVEND-19 phase 3 US ... Novavax phase 2 South Africa ...

18 studies excluded by filtering options 0

5901 Novavax phase 3 UK (2019nCoV-302), 2021 110risk of bias not avaialble
6053 Keech, 2020 110risk of bias not avaialble
6445 Richmond, 2020 000selection pending
6446 Yang, 2020 000selection pending
6505 Goepfert, 2021 000selection pending
7068 Chappell, 2021 010selection pending
8161 Meng, 2021 010selection pending
8241 Shu, 2021 010selection pending
9244 Richardson, 2022 000selection pending
9257 Bravo, 2022 000selection pending
9269 A Community-based Phase 2/3b Study to Assess the Effect of Dose Interval on the Effectiveness of a Protein-based Covid-19 Vaccine (Spikogen® Vaccine), 0 010selection pending
9446 Thuluva, 2022 000selection pending
9450 Shinkai, 2022 010selection pending
9451 Puga-G?mez, 2022 000selection pending
9456 Mahase, 2022 000selection pending
9456 Mahase, 2022 000selection pending
9458 Kaabi, 2022 000selection pending
9484 Liu, 2022 000selection pending